Alonso-Moreno Marta, Mejías-Trueba Marta, Herrera-Hidalgo Laura, Goycochea-Valdivia Walter Alfredo, Gil-Navarro María Victoria
Unidad de Gestión Clínica de Farmacia, Hospital Universitario Virgen del Rocío, 41013 Seville, Spain.
Unidad de Gestión Clínica de Farmacia, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío, 41013 Seville, Spain.
Antibiotics (Basel). 2021 Jul 26;10(8):912. doi: 10.3390/antibiotics10080912.
Vancomycin is used to treat a wide variety of infections within the pediatric population. In adults, continuous infusion of vancomycin (CIV) has been evaluated as an alternative to intermittent infusion of vancomycin (IIV) with potential advantages. In children, the use of CIV is increasing; however, data is currently limited. The objective is to provide efficacy and safety evidence for CIV within this population. The review was carried out following PRISMA guidelines. A bibliographic search was performed for studies on PubMed and EMBASE. Clinical trials and observational studies that reported clinical efficacy and/or target attainment of CIV in pediatrics were included. Articles were reviewed to assess their design and target population, characteristics of vancomycin treatment and the main findings in terms of safety and efficacy. A total of 359 articles were identified, of which seven met the inclusion criteria. All of them evaluated the target attainment, six assessed safety but only three assessed clinical efficacy. The best administration method for this antibiotic within the pediatric population is still unknown due to limited evidence. However, studies conducted thus far suggest pharmacokinetic advantages for CIV. Further investigation is required, in particular for studies comparing IIV with CIV for clinical efficacy and toxicity outcomes.
万古霉素用于治疗儿科患者的多种感染。在成人中,持续输注万古霉素(CIV)已被评估为间歇输注万古霉素(IIV)的替代方法,具有潜在优势。在儿童中,CIV的使用正在增加;然而,目前数据有限。目的是为该人群使用CIV提供有效性和安全性证据。本综述按照PRISMA指南进行。在PubMed和EMBASE上对相关研究进行了文献检索。纳入了报告儿科CIV临床疗效和/或目标达成情况的临床试验和观察性研究。对文章进行了审查,以评估其设计和目标人群、万古霉素治疗的特征以及在安全性和有效性方面的主要发现。共识别出359篇文章,其中7篇符合纳入标准。所有这些文章都评估了目标达成情况,6篇评估了安全性,但只有3篇评估了临床疗效。由于证据有限,该抗生素在儿科人群中的最佳给药方法仍然未知。然而,迄今为止进行的研究表明CIV具有药代动力学优势。需要进一步研究,特别是比较IIV和CIV临床疗效和毒性结果的研究。